黄昕,高爽,梁超,胡晓珺,邬艾佳,沈玲红,何奔

• 1:上海交通大学医学院附属仁济医院心内科

摘要(Abstract)：

<正>对比剂诱发的急性肾损伤(contrast-induced acute kidney injury,CI-AKI)是指对比剂注射后无其他原因可以解释的肾功能急剧下降,又称对比剂肾病(contrast induced nephropathy,CIN)。目前临床上常用血管内注射对比剂后48~72 h内出现的血肌酸酐水平较基础值上升25%或绝对值升高0.5 mg/dl(44μmol/L)以上作为CIN的诊断标

关键词(KeyWords)： 冠心病;经皮冠状动脉介入治疗;对比剂肾病;他汀类药物

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 黄昕,高爽,梁超,胡晓珺,邬艾佳,沈玲红,何奔

参考文献(References)：

• [1]Mc Cullough PA.Contrast-induced acute kidney injury.J Am Coll Cardiol,2008,51(15):1419-1428.
• [2]National Clinical Guideline Centre(UK).Acute Kidney Injury:Prevention,Detection and Management Up to the Point of Renal Replacement Therapy[DB/OL].London:Royal College of Physicians(UK),2013.http://www.ncbi.nlm.nih.gov/books/NBK247665/Pub Med PMID:25340231.
• [3]Ohno Y,Maekawa Y,Miyata H,et al.Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention.J Am Coll Cardiol,2013,62(14):1260-1266.
• [4]Biondi-Zoccai G,Lotrionte M,Thomsen HS,et al.Nephropathy after administration of iso-osmolar and low-osmolar contrast media:evidence from a network meta-analysis.Int J Cardiol,2014,172(2):375-380.
• [5]Anderson JL,Adams CD,Antman EM,et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation,2013,127(23):e663-828.
• [6]Seto AH,Kern MJ.AVERTing contrast nephropathy-delivering less to get more?Catheter Cardiovasc Interv,2015,86(7):1234-1235.
• [7]Brar SS,Shen AY,Jorgensen MB,et al.Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography:a randomized trial.JAMA,2008,300(9):1038-1046.
• [8]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.J Am Coll Cardiol,2011,58(24):e44-e122.
• [9]Fliser D,Laville M,Covic A,et al.A European Renal Best Practice(ERBP)position statement on the Kidney Disease Improving Global Outcomes(KDIGO)clinical practice guidelines on acute kidney injury:part 1:definitions,conservative management and contrast-induced nephropathy.Nephrol Dial Transplant,2012,27(12):4263-4272.
• [10]Jang JS,Jin HY,Seo JS,et al.Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury-a systematic review and meta-analysis.Circ J,2012,76(9):2255-2265.
• [11]Markota D,Markota I,Starcevic B,et al.Prevention of contrastinduced nephropathy with Na/K citrate.Eur Heart J,2013,34(30):2362-2367.
• [12]Firouzi A,Maadani M,Kiani R,et al.Intravenous magnesium sulfate:new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention.Int Urol Nephrol,2015,47(3):521-525.
• [13]Agarwal SK,Mohareb S,Patel A,et al.Systematic oral hydration with water is similar to parenteral hydration for prevention of contrast-induced nephropathy:an updated metaanalysis of randomised clinical data.Open Heart,2015,2(1):e000317.
• [14]Jurado-Román A,Hernández-Hernández F,García-Tejada J,et al.Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention.Am J Cardiol,2015,115(9):1174-1178.
• [15]Briguori C,Visconti G,Focaccio A,et al.Renal Insufficiency After Contrast Media Administration Trial II(REMEDIAL II)Renal Guard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury.Circulation,2011,124(11):1260-1269.
• [16]Marenzi G,Ferrari C,Marana I,et al.Prevention of contrast nephropathy by furosemide with matched hydration:the MYTHOS(Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention)trial.JACC Cardiovasc Interv,2012,5(1):90-97.
• [17]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [18]Brar SS,Aharonian V,Mansukhani P,et al.Haemodynamicguided fluid administration for the prevention of contrast-induced acute kidney injury:the POSEIDON randomised controlled trial.Lancet,2014,383(9931):1814-1823.
• [19]Alpert MA.Do statins reduce the risk of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary interventions?J Am Coll Cardiol,2014,63(1):80-82.
• [20]Gandhi S,Mosleh W,Abdel-Qadir H,et al.Statins and contrast-induced acute kidney injury with coronary angiography.Am J Med,2014,127(10):987-1000.
• [21]Mario Leoncini,Toso A,Maioli M,et al.Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome results from the PRATO-ACS study.J Am Coll Cardiol,2014,63(1):71-79.
• [22]Quintavalle C,Fiore D,De Micco F,et al.Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury.Circulation,2012,126(25):3008-3016.
• [23]Han Y,Zhu G,Han L,et al.Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.J Am Coll Cardiol,2014,63(1):62-70.
• [24]Singh N,Lee JZ,Huang JJ,et al.Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population:systematic review and meta-analysis.Open Heart,2014,1(1):e000127.
• [25]ACT Investigators.Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography main results from the randomized Acetylcysteine for Contrast-Induced Nephropathy Trial(ACT).Circulation,2011,124(11):1250-1259.
• [26]Thiele H,Hildebrand L,Schirdewahn C,et al.Impact of highdose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.The LIPSIA-N-ACC(Prospective,Single-Blind,Placebo-Controlled,Randomized Leipzig Immediate Percutaneou S Coronary Intervention Acute Myocardial Infarction N-ACC)Trial.J Am Coll Cardiol,2010,55(20):2201-2209.
• [27]Sadat U,Usman A,Gillard JH,et al.Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography:a systematic review with metaanalysis of randomized,controlled trials.J Am Coll Cardiol,2013,62(23):2167-2175.
• [28]Lee PT,Chou KJ,Liu CP,et al.Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis:a randomized controlled trial.J Am Coll Cardiol,2007,50(11):1015-1020.
• [29]Guastoni C,Bellotti N,Poletti F,et al.Continuous venovenous hemofiltration after coronary procedures for the prevention of contrast-induced acute kidney injury in patients with severe chronic renal failure.Am J Cardiol,2014,113(4):588-592.